Artificiality

ASP Isotopes Inc. Enters Into Purchase Agreement With a Leading Semiconductor Company for the Supply of Highly Enriched Electronic Gases

Retrieved on: 
Monday, April 1, 2024
Isotope, Icelandic, Silane, Artificiality, Particle, Artificial intelligence, ASP, Silicon, Silicon tetrafluoride, Semiconductor, ASPI

WASHINGTON, April 01, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has entered into a purchase agreement with an industry leader in the design and manufacturing of semiconductors. Under the terms of the agreement, ASP Isotopes expects to supply highly enriched silicon-28 to the customer for use in next-generation semiconductors. The product is expected to be supplied from the Company’s South African production facility and shipped to the customer in the USA during 2024.

Key Points: 
  • - Purchase agreement covers supply of highly enriched silicon-28, which is expected to be supplied in 2024.
  • -ASP Isotopes Inc. is in discussions with multiple semiconductor manufacturers regarding the supply of highly enriched isotopically pure electronic gases for next-generation semiconductors, anticipated to enable technologies such as quantum computing and artificial intelligence.
  • Under the terms of the agreement, ASP Isotopes expects to supply highly enriched silicon-28 to the customer for use in next-generation semiconductors.
  • Highly enriched silicon-28 is spin-free where qubits are protected from sources of decoherence that causes loss of quantum information(1).

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Ovarian cancer, California Department, Conference call, Conference, Development, MicroRNA, Artificiality, Patient, Travel, Cancer, Information technology, AUP, Society, Gynaecology, AACR, Poster, Medicare, Marketing, CMS, Human resources, Federal, Medi-Cal, Cryptocurrency

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.
  • Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.
  • Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022.
  • Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement.

Technogym Ecosystem: the Open Platform that connects equipment from any brand

Retrieved on: 
Monday, April 8, 2024
Mastercard, Google Pay, Health, ROI, Ecosystem, Artificiality, Artificial intelligence, Software, Apple Pay, Wellness, FIBO

COLOGNE, Germany, April 8, 2024 /PRNewswire/ -- Over the years Technogym has developed a unique ecosystem made of connected smart equipment, software, apps, artificial intelligence, on-demand exercise content and tech services. This allows end-users to live a frictionless experience fully personalized on their goals, passions and aspirations and operators to personalize every aspect of a member's gym experience, from assessment to program customization and follow-up, improving member's experiences and increasing ROI thanks to the surge in the attraction rate, retention, upselling and secondary spend. Moreover AI-based Technogym Ecosystem Coach adjusts training programs to enhance engagement and maximize results and supports marketing efforts through advanced profiling, allowing operators to run loyalty campaigns.

Key Points: 
  • At FIBO 2024 in Cologne Technogym introduces the new TECHNOGYM CHECK UP and reinforces TECHNOGYM ECOSYSTEM OPEN PLATFORM STRATEGY, the one and only AI based open platform that integrates equipment from any brand and over 140 software and apps
    COLOGNE, Germany, April 8, 2024 /PRNewswire/ -- Over the years Technogym has developed a unique ecosystem made of connected smart equipment, software, apps, artificial intelligence, on-demand exercise content and tech services.
  • Moreover AI-based Technogym Ecosystem Coach adjusts training programs to enhance engagement and maximize results and supports marketing efforts through advanced profiling, allowing operators to run loyalty campaigns.
  • The brand-new Technogym Checkup – native to Technogym Ecosystem and launching at FIBO 2024 – makes up the ultimate access point to Technogym Ecosystem.
  • This innovative AI-based assessment station is the way to personalize each single training programme: Technogym Checkup scans body composition, analyses strength performances (from activities on strength machines within Technogym Ecosystem), balance, mobility and cognitive abilities.

Technogym Ecosystem: the Open Platform that connects equipment from any brand

Retrieved on: 
Monday, April 8, 2024
Mastercard, Google Pay, Health, ROI, Ecosystem, Artificiality, Artificial intelligence, Software, Apple Pay, Wellness, FIBO

COLOGNE, Germany, April 8, 2024 /PRNewswire/ -- Over the years Technogym has developed a unique ecosystem made of connected smart equipment, software, apps, artificial intelligence, on-demand exercise content and tech services. This allows end-users to live a frictionless experience fully personalized on their goals, passions and aspirations and operators to personalize every aspect of a member's gym experience, from assessment to program customization and follow-up, improving member's experiences and increasing ROI thanks to the surge in the attraction rate, retention, upselling and secondary spend. Moreover AI-based Technogym Ecosystem Coach adjusts training programs to enhance engagement and maximize results and supports marketing efforts through advanced profiling, allowing operators to run loyalty campaigns.

Key Points: 
  • At FIBO 2024 in Cologne Technogym introduces the new TECHNOGYM CHECK UP and reinforces TECHNOGYM ECOSYSTEM OPEN PLATFORM STRATEGY, the one and only AI based open platform that integrates equipment from any brand and over 140 software and apps
    COLOGNE, Germany, April 8, 2024 /PRNewswire/ -- Over the years Technogym has developed a unique ecosystem made of connected smart equipment, software, apps, artificial intelligence, on-demand exercise content and tech services.
  • Moreover AI-based Technogym Ecosystem Coach adjusts training programs to enhance engagement and maximize results and supports marketing efforts through advanced profiling, allowing operators to run loyalty campaigns.
  • The brand-new Technogym Checkup – native to Technogym Ecosystem and launching at FIBO 2024 – makes up the ultimate access point to Technogym Ecosystem.
  • This innovative AI-based assessment station is the way to personalize each single training programme: Technogym Checkup scans body composition, analyses strength performances (from activities on strength machines within Technogym Ecosystem), balance, mobility and cognitive abilities.

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

Retrieved on: 
Wednesday, March 20, 2024
Tendinopathy, Artificiality, Health, Patient, Conditional sentence, History, Artificial intelligence, Lantern, Mantle cell lymphoma, OTCQX, Microsoft HoloLens, Context, Corporation, NEO, Microsoft, Automation, MCL, DHL, Splenic infarction, Diabetes, Risk, PALM, Radiology, Software, Treatment, UiPath, OTCQB, Strategic alliance, Prevalence, Disease, Microsoft Mesh, Hospital, Research, News, WELL, Student, TSX, MPH, Nursing, Machine learning, Diagnosis, TED (conference), OSCE, Growth, Cancer, Trust, Sarcoma, NHL, Appendicitis, Ecosystem, Probability, AIDX, Medical device

A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.
  • MarketsAndMarkets continued: “Based on component, the AI in medical diagnostics market is bifurcated into software, services, and hardware.
  • The software segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.
  • The hospitals segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.

Clover Health Launches New Clinical Program in Partnership with Quartet Health to Address Serious Mental Illness

Retrieved on: 
Tuesday, March 19, 2024
Learning, Artificiality, Clover Health, Partnership, Risk, Patient, Quartet, Transport, Quality of life, Artificial intelligence, Medicine, CMO, SMI, DSM-IV codes, Social, Palliative care, Physician, Practitioner, Nursing

FRANKLIN, Tenn., March 19, 2024 (GLOBE NEWSWIRE) -- Today, Clover Health (“Clover” or the “Company”) announced a partnership with Quartet Health, a value-based behavioral health care enablement and delivery company, to increase the support and resources provided to Clover members with serious mental illness (SMI) through the Company’s home-based care delivery unit, Clover Home Care.

Key Points: 
  • FRANKLIN, Tenn., March 19, 2024 (GLOBE NEWSWIRE) -- Today, Clover Health (“Clover” or the “Company”) announced a partnership with Quartet Health, a value-based behavioral health care enablement and delivery company, to increase the support and resources provided to Clover members with serious mental illness (SMI) through the Company’s home-based care delivery unit, Clover Home Care.
  • As part of this partnership, Quartet will use its expert care teams to augment Clover Home Care’s capabilities.
  • Quartet’s clinicians will also begin using the Clover Assistant platform to deliver care to the Clover patients under its care.
  • As of January 1, Clover Home Care with Whole Health by Quartet Health is available to eligible members in New Jersey for no additional cost.

VERSES Names Analog CEO Alex Kipman as Strategic Advisor & Closes US$2M Investment

Retrieved on: 
Monday, March 18, 2024
Microsoft, TED (conference), PAMI, Conference, Artificiality, Debtor, Intelligence, Internet of things, Partnership, Pattern, Internet, Microsoft Mesh, Artificial intelligence, Equity, Computer vision, Finance Secretary (India), Ecosystem, Machine learning, Microsoft HoloLens, CBOE, Corporation, Cryptocurrency

VANCOUVER, British Columbia, March 18, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”), a cognitive computing company developing next-generation intelligent software systems, announces that Alex Kipman, CEO and Founder of Analog AI has joined as a Strategic Advisor.

Key Points: 
  • VANCOUVER, British Columbia, March 18, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”), a cognitive computing company developing next-generation intelligent software systems, announces that Alex Kipman, CEO and Founder of Analog AI has joined as a Strategic Advisor.
  • Mr. Kipman spent over two decades at Microsoft, most recently in the role of Corporate Vice President/Technical Fellow, Mixed Reality and Artificial intelligence.
  • In doing so, Mr. Kipman helped shape the go-to-market strategy and curated an ecosystem of partners to manage the system from development, to manufacturing, to distribution.
  • “We are excited to engage Alex as an advisor and to leverage his relationships and years of experience,” said Gabriel René, founder and CEO of VERSES.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Medical Devices, FDA, Health, Health Technology, General Health, Pharmaceutical, Eli Lilly, Combination, DCT, Microsoft Research, Artificiality, Trust (social science), GSK, Novartis, Patient, Food and Drug Administration, Artificial intelligence, USS Midway, AI, EMA, Merck & Co., Medicine, European Medicines Agency, Johnson & Johnson, Ecosystem, Drug development, Pharmacovigilance, Food, DIA, Student, Diamond, DEI, Medical device

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points: 
  • The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
  • Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
  • "This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
  • — An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

Availity Launches Groundbreaking AI Claims Denial Prediction Tool, Powered by Anomaly Insights

Retrieved on: 
Tuesday, April 2, 2024
Data Management, Technology, Professional Services, Health, Payments, Health Technology, Apps, Applications, Software, Artificial Intelligence, Networks, Insurance, Database, Artificiality, Partnership, Artificial intelligence, AI, Workflow, Pharmacy, API, Product management, Medical device

Predictive Editing’s engine, powered by artificial intelligence (AI), helps prevent claims denials by analyzing extensive claims data to identify potential denials prior to submission at the front-end of the provider’s submission workflow, allowing for timely corrections and smoother adjudication.

Key Points: 
  • Predictive Editing’s engine, powered by artificial intelligence (AI), helps prevent claims denials by analyzing extensive claims data to identify potential denials prior to submission at the front-end of the provider’s submission workflow, allowing for timely corrections and smoother adjudication.
  • In a recent proof-of-concept study of more than 100 million claims from two large health systems, the Predictive Editing tool demonstrated impressive results, flagging more than $828 million denials with 97% precision.
  • The Predictive Editing tool analyzes millions of historical claims, comparing them to remittance data to detect payment patterns.
  • “Our partnership with Availity provides a unique opportunity to bring advanced AI/ML capabilities directly to providers and payers to eliminate cost and waste.”